Innoplexus launches iPlexus

Innoplexus, the technology and product development company focused on AI and advanced analytics, today announced the launch of its product iPlexus, an end to end platform for Life Sciences which leverages artificial intelligence to generate continuous intelligence and insights across discovery, clinical development, regulatory and commercial stages of drug development, spanning all major therapeutic areas and indications.

iPlexus facilitates better ways of discovering, exploring and analysing biomedical research. The platform has crawled, curated and indexed hundreds of terabytes of scientific data across hundreds of clinical trial databases, biological databases, major patent offices, congresses, theses, forums, regulatory bodies and much more.

Users get quick, crisp and summarized snapshots of the current landscape in any given context, be it important deals and mergers, fast-tracked clinical trials etc, helping them make informed and data-backed decisions. In the drug development process, traditionally, there was a lack of a single source of information for reference.

Speaking on the launch, Dr Gunjan Bhardwaj, Founder and Chairman, Innoplexus, commented, “We are extremely excited to launch iPlexus. Traditionally, both production and consumption of intelligence and insights in enterprises remain predominantly manual. In the current scenario of big data, analytics and machine learning, teams of analysts in companies still curate data manually.

These companies then sell it to customers at very high prices. Today, the volume, velocity, variability and veracity of data makes this manual process impossible. Our goal is to make access to insights real-time, comprehensive and cost effective.

iPlexus ensures instant availability of insights across deep, dense and diverse data sets for taking informed decisions in key therapeutic areas, while saving time and effort from collecting and updating the same information from different sources manually.

The platform makes use of machine learning and AI to generate continuous intelligence. It’s also a mission to democratise data and insights for small and medium organisations which cannot afford traditional offerings.”